Key result
Digitalis provides a small but definite hemodynamic and clinical improvement in patients with congestive heart failure and is suited for those with supraventricular arrhythmias.
Why the study?
Does digitalis provide clinical benefit in patients with congestive heart failure and supraventricular arrhythmias?
Does digitalis provide clinical benefit in patients with congestive heart failure and supraventricular arrhythmias?
Digitalis remains a useful therapeutic option for patients with concurrent supraventricular arrhythmias and compromised left ventricular function.
Answers are grounded in this paper and cite their sources.
May support digitalis in HF with supraventricular arrhythmias; leaves open confirmation in contemporary randomized trials.
Since the initial introduction of digitalis 200 years ago by Withering, its low therapeutic ratio has limited the use of this agent. The utility of digitalis in patients with congestive heart failure and a recent myocardial infarction has been questioned recently. Findings of rigorously controlled clinical studies suggest a small but definite hemodynamic and clinical improvement in patients administered digitalis. Congestive heart failure can be effectively treated without cardiac glycosides. However, when used judiciously, digitalis provides an additional agent in our therapeutic armamentarium. The inotropic, dormotropic, and vagomimetic properties are uniquely suited for the patient with supraventricular arrhythmias and compromised left ventricular function.
No takes yet. Share an insight, caveat, or question.
Somberg et al. (1985) conducted a review in Congestive heart failure, recent myocardial infarction, supraventricular arrhythmias. Digitalis was evaluated. Digitalis provides a small but definite hemodynamic and clinical improvement in patients with congestive heart failure and is suited for those with supraventricular arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: